Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2012; 33(01): 7-12
DOI: 10.4103/0971-5851.96961
REVIEW ARTICLE

Cervical cancer in India and HPV vaccination

K Kaarthigeyan
Department of Pediatrics, PSG Institute of Medical Sciences and Research, Coimbatore, Tamil Nadu, India
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints

Abstract

Cervical cancer, mainly caused by Human Papillomavirus infection, is the leading cancer in Indian women and the second most common cancer in women worldwide. Though there are several methods of prevention of cervical cancer, prevention by vaccination is emerging as the most effective option, with the availability of two vaccines. Several studies have been published examining the vaccine′s efficacy, immunogenicity and safety. Questions and controversy remain regarding mandatory vaccination, need for booster doses and cost-effectiveness, particularly in the Indian context.

Keywords

Cancer - cervix - human papillomavirus - vaccine


Publication History

Article published online:
13 April 2022

© 2012. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Schiffman M, Castle PE, Jeronim J, Rodrigue AC, Wacholde S. Human papillomavirus and cervical cancer. Lancet 2007;370:890-907.
  • 2 Sankaranarayanan R, Ferlay J. Worldwide burden of gynecological cancer: The size of the problem. Best Pract Res Clin Obstet Gynaecol 2006;20:207-25.
  • 3 Singh N. HPV and Cervical cancer - prospects for prevention through vaccination. Indian J Med Paediatr Oncol 2005;26:20-3.
  • 4 WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Summary report on HPV and cervical cancer statistics in India 2007. Available from: http://www.who.int/hpvcentre. [Last Assessed on 2008 May 1].
  • 5 Howley PM, Lowy DR. Papillomaviruses and their replication, chapter 65. Field′s Virology. In: Knipe DM, Howley PM, Editors. 4 th ed. Volume 2, Philadelphia: Lippincott Williamsand Wilkins; 2001. p. 2197-229.
  • 6 Burd EM. Human Papillomavirus and cervical cancer. Clin Microbiol Rev 2003;16:1-17.
  • 7 Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Eng J Med 2003;348:518-27.
  • 8 World Health Organization. HPV IARC monograph summary. Lancet Oncol 2005;6:204.
  • 9 Dunne EF, Markowitz LE. Genital human Papillomavirus infection. Clin Infect Dis 2006;43:624-9.
  • 10 Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000;181:1911-9.
  • 11 Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000;151:1158-71.
  • 12 Bosch FX, de Sanjosé SS. Human papillomavirus and cervical cancer - burden and assessment of causality. J Natl Cancer Inst Monogr 2003;31:3-13.
  • 13 Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. HPV in the etiology of human cancer. Vaccine 2006;24: S1-10.
  • 14 Castellsague X, Munoz N. Cofactors in human papillomavirus carcinogenesis - role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 2003;31:20-8.
  • 15 Winer RL, Hughes JP, Feng Q, O′Reilly S, Kiviat NB, Holmes KK, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006;354:2645-54.
  • 16 Ferenczy A, Franco E. Cervical-cancer screening beyond the year 2000. Lancet Oncol 2001;2:27-32.
  • 17 Huang CM. Human Papillomavirus and vaccination. Mayo Clin Proc 2008;83:701-7.
  • 18 Singhal T. Indian Academy of Pediatrics Committee on Immunisation (IAPCOI) - Consensus Recommendations on Immunization 2008. Indian Pediatr 2008;45:635-48.
  • 19 Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human Papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: A randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
  • 20 Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with Human Papillomavirus types 16 and 18 in young women: A randomized controlled trial. Lancet 2004;364:1757-65.
  • 21 Centers for Disease Control and Prevention. Quadrivalent Human Papillomavirus Vaccine Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007;56:(No. RR-2):1-32.
  • 22 Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, et al. Immunologic responses following administration of a vaccine targeting human Papillomavirus Types 6, 11, 16, and 18. Vaccine 2006;24:5571-83.
  • 23 Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006;95:1459-66.
  • 24 Schiller JT, Frazer IH, Lowy DR. Human Papillomavirus vaccines. In: Plotkin SA, Orenstein WA, editors. Vaccines. 5 th ed. Philadelphia: Saunders; 2008. p. 243-57.
  • 25 Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56:1-24.
  • 26 Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56(RR-2):1-24. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5602a1.htm. [Last Accessed on 2008 Apr 28].
  • 27 American College of Obstetricians and Gynecologists. HPV Vaccine - ACOG Recommendations. Available from: http://www.acog.org/departments/dept_notice.cfm?recno=7andbulletin=3945. [Last Accessed on 2008, April 28].
  • 28 Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, et al. Gynaecologic Cancer Advisory Group. American Cancer Society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007;57:7-28.
  • 29 Choudhury P, John TJ. Human papilloma virus vaccines and current controversy. Indian Pediatr 2010;47:724-5.
  • 30 Choudhury P, Yewale V. Human papilloma virus vaccines and current controversy-reply. Indian Pediatr 2011;48:248-9.